newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

  • Ascentage Pharma Group International announced that its two core assets, lisaftoclax & olverembatinib, are covered by China's 2026 National Reimbursement Drug List (NRDL).
  • Lisaftoclax received its first-time NRDL inclusion for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.
  • Olverembatinib successfully renewed its NRDL coverage for (1) adult patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs); and (2) adult patients with CML-CP or accelerated phase (CML-AP) harboring the T315I mutation.
  • All approved indications for both lisaftoclax & olverembatinib are now covered by the NRDL, with the updated list taking effect on January 1, 2027.
  • Lisaftoclax is a novel, oral, Bcl-2 selective inhibitor approved in China in July 2025, representing the first domestically developed original Bcl-2 inhibitor to receive marketing approval in the country.
  • Olverembatinib is a novel, oral, third-generation BCR-ABL inhibitor approved in China in November 2021, which is jointly commercialized by Ascentage Pharma & Innovent Biologics.
  • Both drugs remain under investigation for US FDA approval & have not yet received US FDA approval.
  • Ascentage Pharma is conducting global registrational Phase III trials for olverembatinib (POLARIS-1, POLARIS-2, POLARIS-3) & lisaftoclax (GLORA, GLORA-2, GLORA-3, GLORA-4) in various hematologic malignancies.
Company
ASCENTAGE PHARMA GROUP INTERNATIONAL
Keywords
Hong Kong Stock Exchange:6855, ASCENTAGE PHARMA GROUP INTERNATIONAL